In this study, 46 different cannabis oil samples were collected .. -0c60–4f ab41db5b3e57c/language-en (accessed April 13, ). Language: English | Spanish | French . However, in another study, cannabis users and controls performed equally well in a working memory task and a. Learning the Language. CBD – or cannabidiol – is a type of cannabinoid, a chemical that's naturally found in cannabis plants, which is where concern generally.
Language Learning the Cannabinoids? Cannabidiol?
Cannabidiol reduces seizure frequency in epilepsy of children and young adults. A Phase 1a Study. A significant reduction in pain intensity was achieved after cannabis inhalation with a vaporizer.
Nabiximols as an agonist replacement therapy during cannabis withdrawal: Significant improvements in pain, sleep quality and subjective evaluations of patients. Effects of cannabidiol in the treatment of patients with Parkinson's disease: Significant improvement in well-being. No effects on motor functioning or neuroprotection. Endocannabinoids control platelet activation and limit aggregate formation under flow.
Activation of cannabinoid receptors by cannabis use reduces platelet activation and blood clotting. A positive THC screen is associated with decreased mortality in adult patients sustaining TBI [traumatic brain injury].
Safety and pharmacokinetics of oral deltatetrahydrocannabinol in healthy older subjects: A woman with intractable nausea after cerebellar stroke responded well to a treatment with THC. Nabilone caused significant improvements in insomnia, nightmares, chronic pain and other symptoms in patients suffering from posttraumatic stress disorder PTSD. Cannabis medical marijuana treatment for motor and non-motor symptoms of Parkinson disease: Analysis of specific motor symptoms revealed significant, also sleep and pain improvement after treatment with cannabis.
Using cannabis to help you sleep: Patients with high PTSD scores were more likely to use cannabis to improve sleep, and for coping reasons more generally.
THC treatment yielded a shift in EEG electroencephalogram power toward delta and theta frequencies and a strengthening of normal rhythms in the sleep.
Clinical experience with THC: CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. A treatment with oral THC was associated with significant decreases in agitation, as well as improvements in sleep duration and appetite.
A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. THC, which was given for 36 months, had no effect on progression compared to placebo.
Objective ratings of opiate withdrawal decreased in patients using cannabis during stabilization. Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. In pain patients, oral dronabinol has similar psychoactive effects to smoking cannabis. The cannabis extract Sativex was generally well tolerated, with no evidence of a loss of effect for pain relief.
No significant difference between placebo and Sativex in Phase A; Phase B demonstrated an analgesic effect. Cannabis induces a clinical response in patients with Crohn's disease: Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers.
Higher THC concentrations were significantly associated with less difficulty falling asleep and more daytime sleep the following day. The medical necessity for medicinal cannabis: In an open clinical study with cancer patients all symptoms improved significantly. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: The use of cannabis did not accelerate progression to significant liver fibrosis.
Impact of cannabis use during stabilization on methadone maintenance treatment. Symptoms of opiate withdrawal decrease in patients undergoing methadone maintenance treatment, who use cannabis.
Treatment failure of intrathecal baclofen and supra-additive effect of nabiximols in multiple sclerosis-related spasticity: A combination of baclofen injections into the cerebrospinal fluid and very low doses of the cannabis extract Sativex was highly effective. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. THC dronabinol and smoked cannabis marijuana caused similar effects on pain sensitivity and pain tolerance.
Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. A new multiple sclerosis spasticity treatment option: The cannabis extract sativex is effective in a large number of patients and well-tolerated in the long-term.
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Sativex appears to be a well-tolerated and useful add-on therapy in patients with spasticity due to multiple sclerosis. Less than one third of self-reported users mention a relief of their attacks following inhalation.
The dose effects of short-term dronabinol oral THC maintenance in daily cannabis users. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Smoked cannabis for spasticity in multiple sclerosis: Acute effects of a single, oral dose of d9-tetrahydrocannabinol THC and cannabidiol CBD administration in healthy volunteers.
Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee.
Herbal cannabis use in patients labeled as fibromyalgia is associated with negative psychosocial parameters. Cannabis derivatives therapy for a seronegative stiff-person syndrome: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
Significant improvement by the cannabis extract Cannador of spasticity and pain. Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia.
Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: Improvement in general health perception, social functioning, ability to work, physical pain and depression; weight gain; average rise in BMI; average Harvey-Bradshaw index was reduced.
A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Cannabis administration was associated with significant increases in plasma levels of ghrelin and leptin, and decreases in PYY, but did not significantly influence insulin levels. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation.
Patients with epilepsy were able to control their seizures by the use of cannabis. No superior analgetic effect of the synthetic cannabinoid GW over placebo. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: In 6 of 13 subjects blood pressure increased significantly after cessation of cannabis use. Deltatetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Neural basis of anxiolytic effects of cannabidiol CBD in generalized social anxiety disorder: The cannabinoid receptor agonist deltatetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients.
Cannabis use in patients with fibromyalgia: The use of cannabis was associated with reduction of some fibromyalgia symptoms.
Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety. Spontaneous regression of benign brain tumour may have been associated with cannabis use. Medical cannabis use in post-traumatic stress disorder: In most cases a significant improvement in quality of life and pain, with some positive changes in severity of posttraumatic stress disorder was observed.
The medicinal use of cannabis and cannabinoids: Preferred modes of use were smoking of cannabis Dronabinol reduces fasting motility of the colon in IBS patients with diarrhoea. Dronabinol for the treatment of cannabis dependence: THC caused significant improvement in treatment retention and withdrawal symptoms.
Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cannabis use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Tetrahydrocannabinol THC for cramps in amyotrophic lateral sclerosis: There were no effects on cramp intensity, number of cramps and fasciculation intensity. Oral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Dramatic improvement of refractory Isaacs' syndrome after treatment with dronabinol. Dramathic improvement of symptoms profuse sweating, muscular twitching, weight loss.
The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Cannabis was superior to placebo in reducing nausea and vomiting in patients refractory to other medications.
Effect of dronabinol on central neuropathic pain after spinal cord injury: Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
In bipolar disorder subjects, cannabis use was associated with better neurocognitive function, but the opposite was the case for the schizophrenia subjects. Depression is a Major Confounding Factor.
The effects of nabilone on sleep in fibromyalgia: Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Smoked medicinal cannabis for neuropathic pain in HIV: Treatment of a hyperkinetic movement disorder during pregnancy with dronabinol.
Effect of Delta 9 -tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: Participants rated cannabis as similar effective as other medications for the treatment of their symptoms.
Systemic bioavailability of the cannabinoid CRA13 increased by more than 4-fold if taken together with a fat-rich meal. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Synthetic deltatetrahydrocannabinol dronabinol can improve the symptoms of schizophrenia. Improvement in 4 of 6 participants, of whom 3 showed a significant improvement. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
White matter integrity in adolescents with histories of marijuana use and binge drinking. Brain damage was less in alcohol users who used also cannabis than in alcohol only users. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cannabinoid-induced effects on the nociceptive system: The study provides objective neurophysiological evidence that cannabinoids modulate the nociceptive system.
Use of medical marijuana for treatment of severe intractable nausea after laparoscopic Roux-en-Y gastric bypass surgery: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.
Improvement of appetite and reduction of nausea and vomiting by nabilone and dronabinol THC. Adjunctive nabilone in cancer pain and symptom management: Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Dramatic reduction in the severity of agitation and other behavioural symptoms. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
Nabilone for the treatment of paraneoplastic night sweats: A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy. Similar treatment effects and side effects of cannabinoids compared to other medications. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. A case report and review of the literature. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers.
A medium dose of cannabis reduced pain, while a high dose increased pain induced by capsaicin. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial.
Anorexia of aging in long term care: Dronabinol and marijuana in HIV-positive marijuana smokers: Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Dronabinol was as effective as ondansetron in reducing nausea and vomiting. Combination therapy was not more effective. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy.
THC reduced intraoculat pressure and improved blood circulation in the retina. Significant reduction of pain and improvement of quality of life with nabilone. A Randomised Controlled Study. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. The effect of extreme marijuana use on the long-term course of bipolar I illness: Cannabis decreased the number of depressed days and increased the number of hypomanic days.
Long term marijuana users seeking medical cannabis in California The treatment of spasticity with Delta 9 -tetrahydrocannabinol in persons with spinal cord injury. Spasticity of patients who received cannabis and complied with the study protocol was significantly reduced compared to placebo.
The synthetic cannabinoid nabilone improves pain and symptom management in cancer patients. Synergistic affective analgesic interaction between deltatetrahydrocannabinol and morphine. There was a synergistic effect between THC and morphine on the affective component of pain but not on the sensory component. Application of THC reduced the need of an opioid to treat postoperative pain but the difference to placebo was not significant.
Dronabinol reduces signs and symptoms of idiopathic intracranial hypertension: Reduction in night-time agitation in actigraphy and in the neuropsychiatric inventory NPI.
A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract Cannador for postoperative pain management.
The optimal dose was 10 mg Cannador, effectively reducing postoperative pain without serious side effects. The effect of cannabis on urge incontinence in patients with multiple sclerosis: A pilot clinical study of Delta 9 -tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. THC was well tolerated in this pilot study of intrakranial cannabinoid administration. DeltaTHC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief.
Five of the nine patients withdrew from the study due to side effects. Four patients experienced significant pain relief. Comparison of orally administered cannabis extract and deltatetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: An effective new possibility for treating chronic pruritus.
Topical application of a cream with N-palmitoyl ethanolamine had a good antipruritic effect in most patients. Nabilone caused a significant reduction in pain and improvement of quality of life.
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial.
Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain.
Significant improvement in one case of intractable neuropathic pain and one case of refractory cinv. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis.
Efficacy and safety of dexanabinol in severe traumatic brain injury: Survey of medicinal cannabis use among childbearing women: Postoperative nausea and vomiting was reduced by prophylactic administration of dronabinol and prochlorperazine.
Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Evaluation of herbal cannabis characteristics by medical users: Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: Moderate cannabis use had a positive effect of retention rates and abstinence from cocaine.
A study showed that low doses of CBD- and THC-like cannabinoids encouraged the creation of new nerve cells in animal models, even in aging brains. Cannabinoids are facilitative of the process of bone metabolism—the cycle in which old bone material is replaced by new at a rate of about 10 percent per year, crucial to maintaining strong, healthy bones over time.
CBD in particular has been shown to block an enzyme that destroys bone-building compounds in the body, reducing the risk of age-related bone diseases like osteoporosis and osteoarthritis. In both of those diseases, the body is no longer creating new bone and cartilage cells. CBD helps spur the process of new bone-cell formation, which is why it has been found to speed the healing of broken bones and, due to a stronger fracture callus, decrease the likelihood of re-fracturing the bone bones are 35—50 percent stronger than those of non-treated subjects.
Protects and Heals the Skin The skin has the highest amount and concentration of CB2 receptors in the body. When applied topically as an infused lotion, serum, oil, or salve, the antioxidant a more powerful antioxidant than vitamins E and C  in CBD oil has many benefits and can repair damage from free radicals like UV rays and environmental pollutants. Cannabinoid receptors can be found in the skin and seem to be connected to the regulation of oil production in the sebaceous glands.
In fact, historical documents show that cannabis preparations have been used for wound healing in both animals and people in a range of cultures spanning the globe and going back thousands of years. The use of concentrated cannabis and CBD oils to benefit and treat skin cancer is gaining popularity with a number of well-documented cases of people curing both melanoma and carcinoma-type skin cancers with the topical application of CBD and THC products.
Best known is the case of Rick Simpson, who cured his basal cell carcinoma with cannabis oil and now has a widely distributed line of products. Cannabis applied topically is not psychoactive.
Cannabinoids have been proven to have an anti-inflammatory effect in numerous studies. CBD engages with the endocannabinoid system in many organs throughout the body, helping to reduce inflammation systemically. The therapeutic potential is impressively wide-ranging, as inflammation is involved in a broad spectrum of diseases. The oral use of cannabis and CBD for anxiety appears in a Vedic text dated around BCE, and it is one of the most common uses of the plant across various cultures.
While THC can increase anxiety in some patients, it lowers it in others. However, CBD effects have been shown to consistently reduce anxiety when present in higher concentrations in the cannabis plant. On its own, CBD has been shown in a number of animal and human studies to lessen anxiety.
The stress-reducing effect appears to be related to activity in both the limbic and paralimbic brain areas. A research review assessed a number of international studies and concluded that CBD has been shown to reduce anxiety , and in particular social anxiety, in multiple studies and called for more clinical trials. It is suggested that patients work with a health care practitioner experienced in recommending cannabidiol or medicinal cannabis so that dosage and delivery methods can be developed and fine-tuned on an individual basis.
At the same time, educated and aware patients can be their own highly informed health consultants. For anxiety, CBD products with a ratio of High-CBD cannabinoids can be very effective in reducing chronic anxiety, treating temporary stress, and protecting the body from the physiological effects of both. Varieties high in linalool, a terpene shared with lavender, are known to be effective for relieving anxiety.
Always start with the micro dose to test sensitivity and go up as needed within the dosing range, before going to the next, until symptoms subside. The micro to standard dose is usually recommended to treat stress and anxiety with CBD. For relief of immediate symptoms, as in a panic or anxiety attack, vaporizing or smoking work well.
The medication lasts one to three hours, whereas most ingested products, including CBD oil, take thirty to sixty minutes before taking effect and last six to eight hours.
Herbal vaporizers that use the whole plant are also an effective delivery method. Sublingual sprays or tinctures taken as liquid drops take effect quickly and last longer than inhaled products.
The Cannabis Health Index CHI is an evidence-based scoring system for cannabis in general, not just CBD oil effects and its effectiveness on various health issues based on currently available research data.
Using this rubric and based on eleven studies, cannabis rated in the possible-to-probable range of efficacy for treatment of anxiety.
Elixinol Organic High Potency CBD Capsules Elixinol offers a highly concentrated, high-potency, organic whole-hemp plant CBD oil , which is naturally extracted with carbon dioxide and free of all synthetics and chemicals.
Whole-hemp plant extracts contain synergistic compounds that are believed to enhance the effectiveness and benefits of CBD. Clinical depression is a serious mood disorder characterized by persistent sadness and loss of interest, sometimes leading to decreased appetite and energy and suicidal thoughts. Commonly used pharmaceuticals for depression often target serotonin, a chemical messenger that is believed to act as a mood stabilizer.
The neural network of the endocannabinoid system works similarly to the way that serotonin, dopamine, and other systems do, and, according to some research, cannabinoids have an effect on serotonin levels. Whereas a low dose of THC increases serotonin, high doses cause a decrease that could worsen the condition.
CBD products with a ratio of Specifically, products made with Valentine X or Electra 4 are more energizing, helping relieve depression. When low energy is an issue, sativa or other stimulating strains can be helpful for improving energy and focus when THC can be tolerated.
Varieties that are high in the terpene limonene are recommended for mood elevation. Always start with the micro dose to test sensitivity and go up as needed within the dosing range before going to the next, until symptoms subside.
The micro to standard dose is usually recommended to treat depression. Vaporized or smoked cannabis is recommended for relief of immediate symptoms, or a boost in dosage, and it can also be useful for sleep issues. The Cannabis Health Index CHI is an evidence-based scoring system for cannabis in general, not just CBD effects and its effectiveness on various health issues based on currently available research data. Using this rubric and based on twenty-one studies, cannabis rated in the possible-to-probable range of efficacy for treatment of depression.
Research in called for clinical trials to look into the effectiveness of cannabinoids for bipolar disorder manic depression. It also works on the GABA-glutamate system and the hypothalamic-pituitary-adrenal axis.
Its main role is restoring balance through inhibition when levels are too high and enhancement when they are too low. This is the most likely reason phytocannabinoids in general and CBD specifically are able to regulate depression and anxiety.
The scientific inquiry into cannabis over the past several decades has confirmed that it is an effective and safe analgesic for many kinds of pain. Of all the reasons that people use CBD today, pain is the most common. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Curr Med Res Opin. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.
Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy.
A randomised multicentre single blind comparison of a cannabinoid anti-emetic levonantradol with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Double-blind, randomized, crossover trial of nabilone vs placebo in cancer chemotherapy. A double-blind, controlled trial of nabilone vs. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
Antiemetic effect of tetrahydrocannabinol: Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Antiemetics in patients receiving chemotherapy for cancer: N Engl J Med.
Deltatetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Cannabis and cancer chemotherapy: Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine.
Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients.
Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting.
Comparison of deltatetrahydrocannabinol THC , prochlorperazine PCP and placebo as anti-emetics for cancer-chemotherapy. Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting CINV. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting.
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Short-term effects of cannabinoids in patients with HIV-1 infection: The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome: Effect of dronabinol on nutritional status in HIV infection.
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. The effects of nabilone on sleep in fibromyalgia: Low-dose vaporized cannabis significantly improves neuropathic pain. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: Smoked cannabis for chronic neuropathic pain: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product Sativex in painful diabetic neuropathy: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.
Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. Nabilone for the treatment of pain in fibromyalgia. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: Sativex successfully treats neuropathic pain characterised by allodynia: Cannabis in painful HIV-associated sensory neuropathy: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine Sativex in the treatment of pain caused by rheumatoid arthritis.
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Analgesic effect of deltatetrahydrocannabinol.
A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Effect of smoked cannabis on painful diabetic peripheral neuropathy. Sativex in the treatment of central neuropathic pain due to spinal cord injury: The effects of nabilone on insomnia in fibromyalgia: McGill University Health Center.
Nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia. Sativex versus placebo when added to existing treatment for central neuropathic pain in MS. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Benefit of an add-on-treatment with a synthetic cannabinomimeticum on patients with chronic back pain-a randomized controlled trial. Paper presented at 8th International Conference on Early Psychosis: A multi-centre, double-blind, randomized, controlled trial of oro-mucosal cannabis based medicine in the treatment of neuropathic pain characterized by allodynia.
The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: Randomised controlled trial of cannabis based medicinal extracts CBME in central neuropathic pain due to multiple sclerosis.
Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Effects of smoked marijuana on neuropathic pain.
Medicinal cannabis for painful HIV neuropathy. University of California Davis. Effects of vaporized marijuana on neuropathic pain. Marijuana for HIV-related peripheral neuropathy. A study of sativex in the treatment of central neuropathic pain due to multiple sclerosis. Sativex for treatment of chemotherapy induced neuropathic pain.
Study to evaluate the efficacy of dronabinol Marinol as add-on therapy for patients on opioids for chronic pain. A trial assessing the effect of nabilone on pain and quality of life in patients with fibromyalgia.
A double blind, randomised, placebo controlled parallel group study of cannabis based medicine extract CBME , in the treatment of peripheral neuropathic pain characterised by allodynia. Pilot study of smoked cannabis for chronic neuropathic pain. A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia.
Accessed April 8, A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. Treatment of painful diabetic neuropathy with Sativex a cannabis based medicinal product —results of a randomised placebo controlled trial. Randomized controlled trial of sativex, a cannabis based medicine CBM , in central neuropathic pain due to multiple sclerosis, followed by an open-label extension.
Psychoactive drugs and quality of life. Efficacy of inhaled cannabis on painful diabetic neuropathy. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: Cannabinoids in multiple sclerosis CAMS study: J Neurol Neurosurg Psychiatry.
Multiple sclerosis and extract of cannabis: Smoked cannabis for spasticity in multiple sclerosis: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. The effect of cannabis on urge incontinence in patients with multiple sclerosis: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Cannabis as a symptomatic treatment for MS: Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis—Results of the MUSEC study. The effects of orally administred cannabinoids in multiple sclerosis patients: Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis — results of the MUSEC study. Cannabis-based medicinal extract Sativex produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance.
Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. A study to evaluate the efficacy of Sativex in relieving symptoms of spasticity due to multiple sclerosis.
University of Manitoba, Valeant Canada Limited. Randomized double blind cross over study for nabilone in spasticity in spinal cord injury persons. A multiple randomised controlled trial of cannabinoids on spasticity in multiple sclerosis MS. Gesellschaft fuer klinische Forschung e. Short-term effects off medicinal cannabis on spasticity in multiple sclerosis. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Antipsychotic effects of cannabidiol.
Evaluation of the antipsychotic efficacy of cannabidiol in acute schizophrenic psychosis. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? The efficacy of cannabidiol in the treatment of schizophrenia—A translational approach. Cannabidiol as a new type of an antipsychotic: Effect of sublingual application of cannabinoids on intraocular pressure: Treatment of Tourette syndrome with deltatetrahydrocannabinol delta 9-THC: Delta 9-tetrahydrocannabinol THC is effective in the treatment of tics in Tourette syndrome: Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol delta9-THC on neuropsychological performance.
Accessed September 2, Evid Based Libr Inf Pract. Accessed Month, date, year. Meta-analyses involving cross-over trials: Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis:
Cannabinoids in health and disease
Learning the language of THC and CBD. The language used today to discuss cannabis is rooted in two realms: the realm of THC and the realm. Also, study after study has demonstrated CBD does not get you high. Lack of Effect on Anxiety; CBD's Relevance to Schizophrenia; Cannabis vs. Many patients experienced improvements in behavior, language, sleep. As well as ingestible CBD (also sold as hemp or cannabis oils or capsules) And a study in which CBD seemed to ease anxiety, published in.